Navigation Links
Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
Date:11/30/2011

SEATTLE, Nov. 30, 2011 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported that with its identification of compounds that interact selectively with each of four additional orphan G protein-coupled receptors (GPCRs) – GPR19, GPR20, GPR31 and GPR141 – it has now unlocked over 20 percent of the 77 Class A orphans.  GPCRs represent the premier family of drug targets, with more than 30 percent of currently marketed drugs targeting only 46 GPCRs. There are approximately 120 orphan GPCRs, and Omeros, which expects to unlock a large percentage of these for drug development, is initially targeting Class A orphan GPCRs.

The four additional orphan receptors unlocked by Omeros are linked to important potential indications. GPR19 has been tied to metastatic melanoma, the most advanced stage of melanoma.  GPR20 and GPR141 are expressed in areas of the body associated with gastrointestinal disorders and respiratory/immunologic disorders, respectively.  GPR31 has been implicated in anxiety disorders, which affect approximately 40 million adults in the United States in a given year.  By identifying compounds that interact selectively with each of these four orphan receptors – as for the other 14 orphan GPCRs that it has previously unlocked – Omeros is uniquely able to provide templates to the pharmaceutical industry for the design of proprietary compounds that interact with these receptors.

"We continue to march through the Class A orphan GPCRs and have initiated compound optimization," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros.  "In parallel, we are executing on our intellectual property strategy to protect each unlocked target through a multipronged approach directed to compound structures, uniquely identified signaling pathways and associated therapeutic indications.  C
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Omeros to Present at Rodman and Renshaw 13th Annual Healthcare Conference
2. Omeros to Present at Two Upcoming Conferences
3. Omeros to Present at Future Leaders in the Biotech Industry Conference
4. Omeros to Present at Needham Healthcare Conference
5. Omeros Corporation Awarded $1.7 Million in Grants Under the Qualifying Therapeutic Discovery Project Program
6. Omeros Announces Additional Support from the National Institute on Drug Abuse for Clinical Studies in Addiction Program
7. Omeros Secures $40 Million Committed Equity Financing Facility
8. Omeros To Webcast Presentation at Ninth Annual Needham Healthcare Conference
9. Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
10. Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
11. Omeros Commences Initial Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... NY (PRWEB) August 01, 2014 ... a provider of DNA-based anti-counterfeiting technology and product authentication ... 12, 2014 to discuss its fiscal third quarter results. ... with the SEC by the end of the day ... Sciences, Inc. management will host a conference call beginning ...
(Date:8/1/2014)... AACC, a global scientific and medical professional organization dedicated ... brand identity today that reflects the organization,s commitment to ... and continue to do what they do best: provide ... they need. " The laboratory professionals ... in saving lives and making people healthier," said AACC ...
(Date:8/1/2014)... Once a decision has been made to increase ... how to define your tolerance for lowest cost design ... Director of Facilities Integration at Fluor Industrial Services, Craig ... and special guest Carrier Li, Director in Global Asset ... provide an examination of the Conceptual Design process and ...
(Date:7/31/2014)... City, CA (PRWEB) July 31, 2014 ... as consumers, are increasingly searching for food alternatives ... and nutritional benefits. The food ingredient market has ... budding players such as Vital Force Technology (VFT). ... with more than 4,000 energetic patterns, all tested ...
Breaking Biology Technology:Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 2Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 3AACC Debuts Refreshed Brand Identity 2Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Functional Ingredient Manufacturer – Vital Force Technology Infuses Raw Materials & Ingredients with Subtle Energy Formula 2
... Nov. 21, 2011 WaferGen Biosystems, Inc. (OTCBB:WGBS), an ... the three and nine months ended September 30, 2011 ... adoption of its SmartChip System. "During the ... strategy to address the rapidly changing needs of the ...
... Phase I Single Dose Study Data ... Convergence Pharmaceuticals Limited ("Convergence"), the company focused ... medicines, today announces that the multiple ascending dose Phase ... channel blocker CNV2197944, for the treatment of chronic pain ...
... Japan, November 18, 2011 - A research group from ... and Fujitsu Limited today announced that research results obtained ... Bell Prize, Peak-Performance at SC11, the International Conference for ... in Seattle, on November 17 (US Pacific Standard Time). ...
Cached Biology Technology:WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 2WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 3WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 4WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 5WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 6WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 7WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 8Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 2Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 3Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 4'K computer' research results awarded ACM Gordon Bell Prize 2
(Date:8/1/2014)... Modern humans appear in the fossil record about 200,000 ... ago that making art and advanced tools became widespread. ... the journal Current Anthropology finds that human ... testosterone levels at around the same time that culture ... innovation, making art and rapid cultural exchange probably came ...
(Date:8/1/2014)... examining a taxonomically confused group of marine mammals ... the Australian humpback dolphin, Sousa sahulensis , ... Enterprises. , The study describing the newly ... long systematic examination of all available historical records, ... widespread group of coastal cetaceans ranging from the ...
(Date:8/1/2014)... key component of phloem, the conductive tissue through which ... molecules. Elongated cylindrical cells are capped at one end ... sieve tubes which in turn form a network throughout ... very special cells which play an important role in ... known about their differentiation," says Professor Yk Helariutta from ...
Breaking Biology News(10 mins):Society bloomed with gentler personalities and more feminine faces 2Scientists name new species of cetacean: The Australian humpback dolphin 2Scientists name new species of cetacean: The Australian humpback dolphin 3Developmental regulation of important plant phloem components discovered 2
... indicating that more than 50% of all osteoporotic hip fractures ... and treatment of osteoporotic fractures has become a major health ... Osteoporosis (IOF WCO), to be held for the first time ... the region to attend the leading global congress devoted to ...
... new drug trabectedin with pegylated liposomal doxorubicin provides clinical ... new results presented at the 33rd Congress of the ... The combination, which importantly does not include a ... women whose cancer recurs at least 6 months after ...
... N.C. A newly discovered chemical pathway that helps ... 20 common beta-blockers, drugs that are prescribed to millions ... Researchers from Duke University Medical Center tested 20 beta ... and carvedilol -- could stimulate a pathway recently found ...
Cached Biology News:IOF World Congress on Osteoporosis in Bangkok to address Asian issues 2Promising new treatment option for women with recurrent ovarian cancer 22 beta blockers found to also protect heart tissue 2
... new HydroFlex platform provides excellent performance, ... of 96-well format applications, including washing ... arrays, and vacuum filtration-to-waste, such as ... on-line control features set new standards ...
... Obtain Clean and Accurate Results ... to dramatically increase the sensitivity and accuracy ... of homogeneous cell types and multi-cellular structures ... This unique approach to microdissection-developed in 1996 ...
...
... with 5.6" TFT color screen, without Camera ... digital camera with 8.0 mega pixel resolution. It ... small budget. View image from large 5.6" TFT ... It is suitable to capture image for fluorescent ...
Biology Products: